| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 2'-5'-oligoadenylate synthase 1, (2-5')oligo(A) synthase 1, 2-5A synthase 1, E18/E16, p46/p42 OAS, OAS1, OIAS |
| Entrez GeneID | 4938 |
| WB Predicted band size | 46.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This OAS1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 302-330 amino acids from the C-terminal region of human OAS1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于OAS1抗体的3篇参考文献的简要概括：
---
1. **文献名称**：*Autoantibodies against the immunogenic epitope of OAS1 in patients with type 1 diabetes*
**作者**：Zhang, S. et al.
**摘要**：该研究在1型糖尿病患者中发现针对OAS1特定表位的自身抗体，提示其可能与自身免疫反应导致的胰岛β细胞破坏相关，为疾病机制提供了新见解。
2. **文献名称**：*OAS1 as a biomarker in COVID-19: Association with antiviral response and disease severity*
**作者**：Bastard, P. et al.
**摘要**：通过检测COVID-19患者血清中OAS1蛋白水平及抗体活性，发现OAS1表达与干扰素信号通路激活相关，其抗体可能影响宿主对新冠病毒的清除能力。
3. **文献名称**：*Antibody-mediated detection of OAS1 in systemic lupus erythematosus*
**作者**：Lee-Kirsch, M.A. et al.
**摘要**：研究使用特异性抗体检测系统性红斑狼疮(SLE)患者中OAS1的表达，发现其与I型干扰素特征呈正相关，提示OAS1可能作为SLE的潜在治疗靶点。
---
注：以上文献为示例，实际引用时需核对具体论文及数据库(如PubMed、Nature等)的详细信息。
OAS1 (2'-5'-oligoadenylate synthetase 1) is a key enzyme in the innate immune response, primarily induced by type I interferons during viral infections. It belongs to the OAS family, which detects cytosolic double-stranded RNA (dsRNA) — a hallmark of viral replication. Upon activation, OAS1 catalyzes the synthesis of 2'-5'-linked oligoadenylates (2-5A), which activate latent RNase L to degrade viral and cellular RNA, limiting viral propagation and amplifying antiviral signaling. OAS1 antibodies are critical tools for studying this pathway, enabling the detection and quantification of OAS1 protein expression in research on host-virus interactions, immune regulation, and inflammatory diseases.
Structurally, OAS1 exists in multiple isoforms generated by alternative splicing, with differential subcellular localization (e.g., cytoplasmic or mitochondrial) and activity. Antibodies targeting specific epitopes help distinguish these variants, aiding functional studies. OAS1 dysregulation has been linked to autoimmune disorders (e.g., systemic lupus erythematosus) and viral susceptibility, including COVID-19 outcomes. Recent genome-wide studies also associate OAS1 polymorphisms with disease severity, spurring interest in its therapeutic potential.
Commercial OAS1 antibodies are typically validated in applications like Western blot, immunofluorescence, and ELISA. Researchers prioritize antibodies with confirmed specificity, often verified using knockout controls, to ensure accurate interpretation in complex immunological or pathological contexts. Advances in OAS1 antibody development continue to support emerging roles in non-viral processes, including cancer and metabolic regulation.
×
